A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer

• Sponsor: National University Hospital, Singapore (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT00943891
• Collaborator: (none)
• Enrollment: 500
• Location: 1
• Duration (Months): 77
• Patients Per Site Per Month: 6.5

Study Details

Study Description

Brief Summary

1. To determine the association between LVD and clinico-pathologic variables in archived colorectal cancer and Nasopharyngeal carcinoma specimens

2. To determine the association between VEGF-C,-D expression with COX-2 expression and clinico-pathologic variables in colorectal cancer and Nasopharyngeal carcinoma

3. To determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma Lymphangiogenesis and factors modulating lymphangiogenesis are associated with clinico-pathological outcome in Nasopharyngeal carcinoma and colorectal cancer. Celecoxib down-regulates lymphangiogenesis Archival colorectal cancer and Nasopharyngeal carcinoma tumor specimens will be obtained from the Department of Pathology. To determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma, the investigators intend to analyze archived specimens collected in a previously conducted study. Colorectal tumor and nodal specimens and Nasopharyngeal carcinoma primary will be examined for MVD, LVD and growth factor expression using established haematoxylin and eosin and immunohistochemical techniques. Quantification of LVD and MVD shall be performed by two pathologists blinded to clinico-pathological variables using standardised methods.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer; Nasopharyngeal Cancer	Procedure: Tumor biopsies

Study Design

• Study Type: Observational
• Observational Model: Case-Crossover
• Time Perspective: Cross-Sectional
• Official Title: A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer
• Study Start Date: Jul 1, 2008
• Anticipated Primary Completion Date: Dec 1, 2014
• Anticipated Study Completion Date: Dec 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Tumor biopsies	Procedure: Tumor biopsies

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 21 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Male and female patients are eligible

• Patients 21 years or older

Exclusion Criteria:

• None

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National University Hospital	Singapore		Singapore	119074

Sponsors and Collaborators

• National University Hospital, Singapore

Investigators

• Principal Investigator: Ross Andrew Soo, MBBS, National University Hospital, Singapore

Study Documents (Full-Text)

None provided.

More Information

Publications

• Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001 Feb 15;20(4):672-82.
• Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001 Feb;7(2):186-91.

• ClinicalTrials.gov Identifier: NCT00943891
• Other Study ID Numbers: MC01/09/08
• First Posted: Jul 22, 2009
• Last Update Posted: Jan 22, 2014
• Last Verified: Jan 1, 2014

• Additional relevant MeSH terms: Nasopharyngeal Neoplasms; Nasopharyngeal Carcinoma

Study Results

No Results Posted as of Jan 22, 2014